Australia markets closed

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.58+0.16 (+2.16%)
At close: 04:00PM EDT
7.58 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.42
Open7.47
Bid7.54 x 900
Ask7.56 x 800
Day's range7.34 - 7.60
52-week range4.51 - 22.94
Volume623,805
Avg. volume497,695
Market cap925.874M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.56
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est22.40
  • GlobeNewswire

    Erasca to Present at the Morgan Stanley Global Healthcare Conference

    SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern

  • GlobeNewswire

    Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials

    23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601 ERAS-007 and ERAS-601 had favorable safety and tolerability profiles with largely non-overlapping treatment-related adverse events that support combination development Initiation of ERAS-007 plus ERAS-601 MAPKlamp trial in RAS/MAPK-altered, including BRAF-driven, solid tumors anticipated to begin in fir

  • GlobeNewswire

    Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors

    Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 SAN DIEGO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commer